Mesoblast Limited (ASX: MSB) - Share Price
Current share price for MSB : $2.060 0.01 (0.49%)+
Mesoblast Limited (MSB), an ASX-listed company, is a Company that is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of inflammatory conditions. The therapies from the Company's proprietary mesenchymal lineage cell therapy technology platform respond to inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in reduction of the damaging inflammatory process.
MSB General Information +
| ASX Code | MSB |
| Website | http://www.mesoblast.com |
| Industry/Sector | Biotechnology |
| Market Cap ($M) | 2,666 |
| MSB Share Price | $2.060 |
| Day High | $2.070 |
| Day Low | $2.020 |
| Last Close | $2.050 |
| MSB Share Price Movement | $0.01 ( 0.49% ) |
Prices as at 16:40, 3 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Mesoblast Limited (MSB) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Mesoblast Limited (MSB) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Mesoblast Limited (MSB) price-sensitive announcements
MSB - Mesoblast Draws US$50M from Five-Year Non-Dilutive Facility
Mesoblast Limited has announced the drawdown of US$50 million from a five-year non-dilutiv
Mesoblast Limited (MSB)
25 Jun 2026 | 9:55 AM
25 Jun 2026 | 9:55 AM
MSB - Quarterly Activities/Appendix 4C Cash Flow Report
Mesoblast Limited reported a strong financial and operational quarter for the period endin
Mesoblast Limited (MSB)
30 Apr 2026 | 9:56 AM
30 Apr 2026 | 9:56 AM
MSB - Patient Recruitment Target Achieved in CLBP Pivotal Trial
Mesoblast Limited announced the achievement of its patient recruitment target for the pivo
Mesoblast Limited (MSB)
29 Apr 2026 | 9:50 AM
29 Apr 2026 | 9:50 AM
MSB - Ryoncil Net Revenue for the Quarter Increases to US$30.3M
Mesoblast Limited reported that Ryoncil® (remestemcel-L-rknd) achieved net sales of US$30.
Mesoblast Limited (MSB)
7 Apr 2026 | 10:12 AM
7 Apr 2026 | 10:12 AM
Mesoblast Limited (MSB) Recent ASX Announcements
MSB Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2027F | C2 | -$0.90 | -85.80% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2026F | C2 | -$6.10 | -50.90% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2025A | -$148.88 | -$12.30 | 3.00% | 0.00 | 0.00 | 0.00% | 0.0% |
MSB Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 A | 2026 F | 2027 F | 2025 A | 2026 F | 2027 F | 2025 A | 2026 F | 2027 F | ||
| CSL Limited (CSL) | $56,689M | 0.1108 | -0.1258 | 0.0166 | 12.6929 | 14.5197 | 14.2819 | 3.77% | 3.06% | 3.18% |
| Clinuvel Pharmaceuticals Limited (CUV) | $525M | 0.0287 | 0.0000 | 0.0000 | 14.5125 | 0.0000 | 0.0000 | 0.48% | 0.00% | 0.00% |
| Immutep Limited (IMM) | $84M | 0.1854 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Mesoblast Limited (MSB) | $2,641M | 0.0301 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Telix Pharmaceuticals Limited (TLX) | $5,776M | -1.3893 | 0.0000 | -0.1296 | 0.0000 | 315.1852 | 362.1277 | 0.00% | 0.00% | 0.00% |
MSB Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 2.88 | 0.00 |
| Market | 0.55 | 16.70 | 1.57 | 0.94 |
| Sector | 0.44 | 26.10 | 2.47 | 1.92 |
MSB Directors
| Name | Position | Start Date |
|---|---|---|
| Professor Silviu Itescu | Chief Executive Officer, Executive Director | 8 Jun 2004 |
| Dr Eric A Rose | Executive Director | 15 Apr 2013 |
| Ms Jane Catherine Bell | Non-Executive Director | 18 Aug 2022 |
| Dr Philip R Krause | Non-Executive Director | 24 Mar 2022 |
| Ms Lynette Elizabeth Cobley | Non-Executive Director | 29 Apr 2025 |
| Dr Gregory George | Non-Executive Director | 24 Feb 2025 |
| Mr Philip J. Facchina | Non-Executive Director, Non-Executive Chairman | 29 Mar 2021 |
| Mr William (Bill) A Burns | Non-Executive Director, Vice-Chairman | 6 Mar 2014 |
Mesoblast Limited (MSB) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 10 Apr 2026 | GEORGE, Gregory | Buy | Indirect Shares | 7,210,962 | $1.445 | $10,418,591.090 |
| 9 Apr 2026 | GEORGE, Gregory | Buy | Indirect Shares | 700,000 | $1.445 | $1,011,378.754 |
| 6 Mar 2026 | GEORGE, Gregory | Buy | Indirect Shares | 11,070,522 | $1.479 | $16,370,330.900 |
See all changes in directors' interest & trades for Mesoblast Limited (MSB) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
MSB Management
| Name | Position |
|---|---|
| Eric Rose | Chief Medical Officer |
| Andrew Chaponnel | Chief Financial Officer |
| Peter Howard | Group General Counsel and Corporate Executive |
| Justin Horst | Head of Manufacturing |
| Geraldine Storton | Head of Regulatory Affairs and Quality Management |
| Fiona See | Head of Translational Research |
| Niva Sivakumar | Joint Company Secretary |
| Paul Hughes | Joint Company Secretary |
| Michael Schuster | Pharma Partnering |
| Paul Simmons | Scientific Advisor to the Chief Executive Officer |
MSB Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Mesoblast Limited (MSB). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 267,021,132 (20.86%) | Gregory George Patching |
| 78,958,928 (6.16%) | Silviu Itescu |
| 64,171,900 (5.01%) | William Gueck |
MSB Calendar of Events
| Date | Event |
|---|---|
| 26 February 2027 | Report (Interim) |
| 26 October 2026 | Report (Annual) |
| 28 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
